Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

NCT01282463 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma of Urinary Tract
Urethral Carcinoma
Carcinoma of Ureter
Carcinoma of Renal Pelvis

Interventions

DRUG: Docetaxel
BIOLOGICAL: Ramucirumab DP
BIOLOGICAL: Icrucumab

Sponsor

Eli Lilly and Company